LOTUSEYE112.50

Lotus Eye Hospital and Institute Limited

· Pharma & Health
₹ CrorePeersGPTHEALTHGKSLSHALBYINDRAMEDCOARTEMISMEDDRAGARWQKMCSHILKOVAIMcap ₹234 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Returns
Return on Common Equity4.911.230.13
Return on Assets4.371.060.10
Return on Capital Employed4.640.69-0.50
Return on Invested Capital3.590.39-0.21
Margins
EBITDA Margin13.556.936.30
Operating Margin5.810.86-0.68
Incremental Operating Margin-175.66-19.10
Pretax Margin8.332.79-0.10
Net Income Margin6.051.490.15
FCF Margin0.080.24-18.44
Additional
Effective Tax Rate27.3946.53250.00
Dvd Payout Ratio35.681.4514.55
Sustainable Growth Rate3.161.210.11
Incremental Operating Margin %-175.66-19.10
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.